Hematologic Oncology Update

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
• Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
• Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

• Introduction (00:00)
• Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
• Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
• Utility of Belantamab Mafodotin in R/R MM (49:29)
• Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman, including the following topics:

• The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
• The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
• Zanubrutinib-based therapy for treatment-naïve CLL (12:32)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
• Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
• Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)

CME information and select publications

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:

• Introduction (0:00)
• Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)
• Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)
• Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)
• Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

• Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
• Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
• Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
• Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
• Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
• Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
• Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

• Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
• Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
• Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
• Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:

• Introduction (0:00)
• Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)
• Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)

CME information and select publications

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:

• Introduction (0:00)
• Systemic Mastocytosis — Dr Hunter (9:33)
• Myelofibrosis — Dr Yacoub (29:40)

CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:

• Introduction (0:00)
• Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)
• Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)

CME information and select publications